AI assistant
ImmunityBio, Inc. — Director's Dealing 2024
Dec 17, 2024
31529_dirs_2024-12-16_9ea00b9b-66ce-4ba1-ab5b-4823bf4de387.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2024-12-15
Reporting Person: LAUER REGAN J (Chief Accounting Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-12-15 | Common Stock | M | 21031 | — | Acquired | 115365 | Direct |
| 2024-12-15 | Common Stock | F | 7503 | $2.87 | Disposed | 107862 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-12-15 | Restricted Stock Units | $ | M | 21031 | Disposed | Common Stock (21031) | Direct |
Footnotes
F1: On December 15, 2024, the Reporting Person's restricted stock units ("RSUs") vested. The closing price of Immunity Bio, Inc.'s common stock on December 13, 2024 was the settlement price used to calculate the shares withheld.
F2: Each RSU represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F3: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the RSUs vested as follows: 1/3rd of the RSUs subject to the award vested June 15, 2023, 1/3rd of the RSUs subject to the award vested December 15, 2023, and 1/3rd of the RSUs subject to the award vested December 15, 2024 such that the award was fully vested on December 15, 2024.